Cipla
15 federal recalls on file. We monitor every CPSC, FDA, USDA, and NHTSA notice for Cipla and translate it into plain English — free weekly digest, optional same-day alerts.
- 2026-04-22FDA-DrugClass IIStop using Cipla cinacalcet 90 mg tablets
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
- 2026-04-22FDA-DrugClass IIStop taking Cipla Cinacalcet 60 mg tablets
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
- 2026-04-22FDA-DrugClass IIStop using Cipla Cinacalcet Hydrochloride tablets
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
- 2026-04-15FDA-DrugClass IIStop using Cipla Lanreotide Injection
Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
- 2026-04-15FDA-DrugClass IIDo not use Cipla Lanreotide Injection
Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
- 2026-03-11FDA-DrugClass IIIStop using Cipla Nilotinib capsules, Lot 5GJ0223
Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
- 2026-03-11FDA-DrugClass IIIStop using Cipla Nilotinib 150 mg capsules
Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
- 2026-01-28FDA-DrugClass IIIStop using Cipla Diclofenac Sodium Topical Gel
Failed PH Specifications
- 2026-01-21FDA-DrugClass IIStop using Cipla Lanreotide Injection
Presence of Particulate Matter.
- 2025-12-17FDA-DrugClass IICinacalcet Hydrochloride Tablets, 90 mg, 30 Tablets per bottle, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-412-02
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
- 2025-12-17FDA-DrugClass IICinacalcet Hydrochloride Tablets, 60 mg, 30 Tablets per bottle, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-411-02
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
- 2025-12-17FDA-DrugClass IICinacalcet Hydrochloride Tablets, 30 mg, 30 Tablets per bottle, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-410-02
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
- 2025-12-17FDA-DrugClass IILanthanum Carbonate chewable tablets, 1000mg*, 10x9 bottles per patient pack carton, Rx Only, Manufactured by: Invagen Pharmaceuticals, Inc., (a subsidary of Cipla Ltd) Hauppauge, NY 11786, Manufactured for: Exelan Pharmaceuticals, Inc., Boca Raton, FL 33422, Carton NDC 76282-478-90; Bottle NDC 76282-478-13.
Failed stability specifications: Out of specification for hardness test
- 2025-12-17FDA-DrugClass IILanthanum Carbonate chewable tablets, 1000mg*, 10x9 bottles per patient pack carton, Rx Only, Manufactured by: Invagen Pharmaceuticals, Inc., Hauppauge, NY 11786, Manufactured for : Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, NDC 69097-936-98.
Failed stability specifications: Out of specification for hardness test
- 2025-12-10FDA-DrugClass IIPhytonadione Injectable Emulsion, USP 10mg/mL, 10x1 mL Single-Dose Vial/carton, Rx Only, Mfd. by: Cipla Ltd. India At M/s Immacule Lifesciences PVT. Ltd. India. Mfd. for: Cipla USA, Inc. Warren, NJ 07059. Vial NDC# 69097-708-31; Carton NDC 69097-708-96
Failed Stability Specifications: Observed OOS results: eg results for colour index
Get notified about new Cipla recalls
Free weekly digest. We email when a new federal recall affects Cipla or anything else in your household.
Get the Sunday Brief